Ignite Creation Date:
2024-07-17 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06477237
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-18
Brief Title:
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Sponsor:
Huabo Biopharm Co Ltd
Organization:
Huabo Biopharm Co Ltd
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized double-blind placebo-controlled phase III clinical study which is designed to determine the efficacy safety immunogenicity and pharmacokinetics and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None